 | |
| Clinical data | |
|---|---|
| Other names | CORT-125134 |
| Routes of administration | By mouth |
| Drug class | Antiglucocorticoid |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C27H22F4N6O3S |
| Molar mass | 586.57 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Relacorilant (developmental code nameCORT-125134) is anantiglucocorticoid which is under development by Corcept Therapeutics for the treatment ofCushing's syndrome.[1] It is also under development for the treatment ofsolid tumors andalcoholism.[1][2] The drug is anonsteroidalcompound and acts as anantagonist of theglucocorticoid receptor.[1] As of December 2017, it is inphase IIclinical trials for Cushing's syndrome andphase I/II clinical studies for solid tumors, while the clinical phase for alcoholism is unknown.[1]
 | Thishormonal preparation article is astub. You can help Wikipedia byexpanding it. |